Celemics Inc is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/08/26	₩9,450.00	+1.07%	46,605
03/08/26	₩9,350.00	+3.31%	46,147
31/07/26	₩9,050.00	0.00%	50,988
30/07/26	₩9,050.00	-0.66%	24,636
29/07/26	₩9,110.00	-14.86%	68,264

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 04/08/2026			5-day change	1st Jan Change
9,450.00 ^KRW	+1.07%		-11.68%	+248.07%

06-24	Celemics, Inc. announced that it expects to receive KRW 9.999995577 billion in funding from Cnp Co., Ltd.	CI
05-29	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI

Market Cap	111B 77.97M 67.7M 63.12M 57.99M 110M 7.42B 111M 744M 291M 3.71B 293M 286M 12.28B	P/E 2024	2.19x	P/E 2025	-5.49x
Enterprise Value	106B 74.08M 64.33M 59.98M 55.1M 104M 7.05B 105M 707M 276M 3.52B 278M 272M 11.67B	EV / Sales 2024	2.56x	EV / Sales 2025	2.88x
Free-Float	-	Yield 2024 *	-	Yield 2025	-

06-24	Celemics, Inc. announced that it expects to receive KRW 9.999995577 billion in funding from Cnp Co., Ltd.	CI
05-29	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
04-30	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI
04-28	Celemics, Inc. announced that it has received KRW 14.7 billion in funding	CI
03-31	Celemics, Inc. announced that it expects to receive KRW 11.5999945 billion in funding	CI
03-30	Celemics, Inc. announced that it expects to receive KRW 27 billion in funding	CI
03-13	Park Jong-gap completed the acquisition of an additional 5.27% stake in Celemics, Inc. from Kim Hyo-gi, Lee Yong-hoon.	CI
02-03	Celemics, Inc. announced that it expects to receive KRW 9.2927074 billion in funding	CI
02-03	Park Jong-gap agreed to acquire an additional 5.27% stake in Celemics, Inc. from Hyo-gi Kim, Yong-hoon Lee for KRW 2.6 billion.	CI
19/09/22	Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index	CI
22/03/21	Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index	CI
21/08/20	Celemics, Inc. has completed an IPO in the amount of KRW 26.4 billion.	CI
18/03/20	Celemics, Inc. has filed an IPO.	CI

1 day	+1.07%
1 week	-11.68%
Current month	+4.42%
1 month	-17.68%
3 months	-33.68%
6 months	+163.97%
Current year	+248.07%

Celemics, Inc. Stock

Stocks

A331920

KR7331920009

Biotechnology & Medical Research

Valuation: Celemics, Inc.

Chart: Celemics, Inc.

Latest news : Celemics, Inc.

Press Releases: Celemics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celemics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	8,550	9,920
1 month	8,500	11,600
Current year	2,580	19,840
1 year	2,535	19,840
3 years	2,535	19,840
5 years	2,535	22,350
10 years	2,535	39,400

Manager	Title	Age	Since
Yong-Hun Lee CEO	Chief Executive Officer	61	01/01/2017
Hyo-Gi Kim CEO	Chief Executive Officer	43	01/01/2013
Sang-Seok Lee PRN	Corporate Officer/Principal	45	01/01/2020

Director	Title	Age	Since
Yong-Hun Lee BRD	Director/Board Member	61	01/01/2017
Seung-Kwon Paek BRD	Director/Board Member	62	27/03/2025
Hyo-Gi Kim BRD	Director/Board Member	43	01/01/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELEMICS, INC.	+1.07%	-11.68%	+197.17%	+103.44%	74.05M
LONZA GROUP AG	+0.23%	-2.89%	+0.11%	+13.87%	48B
REVOLUTION MEDICINES, INC.	+1.40%	+8.83%	+412.89%	+564.30%	41.13B
IQVIA HOLDINGS INC.	+3.10%	-5.29%	+27.48%	+6.92%	37.56B
BEONE MEDICINES AG	+2.34%	+1.03%	+7.60%	+76.29%	35.91B
CELLTRION, INC.	+1.98%	+4.74%	+12.19%	+41.37%	29.86B
ASCENDIS PHARMA A/S	+1.01%	-2.66%	-	-	16.12B
MEDPACE HOLDINGS, INC.	+1.47%	-0.17%	+33.83%	+124.24%	16.05B
EUROFINS SCIENTIFIC SE	+1.31%	+1.57%	+4.68%	+18.73%	13.76B
ICON PUBLIC LIMITED COMPANY	+4.77%	-7.81%	-1.03%	-34.70%	12.1B
Average	+1.88%	-1.25%	+77.21%	+101.61%	25.06B
Weighted average by Cap.	+1.79%	-0.93%	+82.17%	+127.74%

	2024	2025
Net sales	6.72B 4.71M 4.09M 3.81M 3.5M 6.62M 448M 6.7M 44.94M 17.57M 224M 17.68M 17.29M 742M	5.77B 4.04M 3.51M 3.27M 3.01M 5.69M 384M 5.75M 38.58M 15.08M 192M 15.18M 14.85M 637M
Net income	12.27B 8.6M 7.46M 6.96M 6.39M 12.09M 818M 12.22M 82.05M 32.07M 409M 32.28M 31.57M 1.35B	-4.04B -2.83M -2.46M -2.29M -2.1M -3.98M -269M -4.02M -27M -10.55M -135M -10.62M -10.39M -446M
Net Debt	-9.55B -6.69M -5.81M -5.42M -4.98M -9.41M -636M -9.51M -63.86M -24.97M -318M -25.13M -24.58M -1.05B	-5.54B -3.88M -3.37M -3.14M -2.89M -5.46M -369M -5.52M -37.06M -14.49M -185M -14.58M -14.26M -612M